Bal Pharma locked in an upper circuit of 20% to Rs 120.18 after the company’s consolidated net profit stood at Rs 5.53 crore in Q4 FY24, steeply higher than Rs 1.61 crore in Q4 FY23.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
